The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored ....Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored to selectively kill microbes with reduced likelihood of developing resistance by using synergies between inorganic nanoparticles and antimicrobial peptides. This technology could be used to prevent infections and biofilms on surfaces in a wide range of future applications, such as medical / veterinary devicesRead moreRead less
Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hya ....Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hyaluronan) of the interstitum, can be used promote absorption into the draining blood and lymph capillaries. The project aims to also explore the downstream effects of hyaluronidase on lymph nodes and evaluate whether the enzyme is able to temporarily disrupt the lymph node structure and promote drug penetration into the lymph node mass. This has significant potential for improved drug targeting.Read moreRead less
Understanding the Cellular Pathways of Nuclear Receptor Activation. The success of drug treatment depends critically on specificity, i.e., stimulation of a therapeutic response at a target site, and avoidance of activity at other (potentially toxic) locations. This project aims to explore how drug interactions with binding proteins in the cytosol can induce nuclear transport and tissue specific activation of nuclear receptors - a major drug target. The project intends to employ molecular, struct ....Understanding the Cellular Pathways of Nuclear Receptor Activation. The success of drug treatment depends critically on specificity, i.e., stimulation of a therapeutic response at a target site, and avoidance of activity at other (potentially toxic) locations. This project aims to explore how drug interactions with binding proteins in the cytosol can induce nuclear transport and tissue specific activation of nuclear receptors - a major drug target. The project intends to employ molecular, structural and cell biology approaches to map drug-binding protein-receptor interactions and to determine how the structure of these complexes dictates receptor activation. The data could provide a roadmap to design drugs that interact with the right protein in the right tissue and in doing so dramatically enhance drug specificity.Read moreRead less
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future ....Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future of natural product discovery and optimisation in the hands of the wider scientific community, which will provide significant benefits, such as providing new tools for Australian industries.Read moreRead less
Next Generation Polymeric Scaffolds For Dual Agent Delivery. This project aims to provide a novel suite of degradable polymeric scaffolds for releasing multiple active agents with tailored release profiles by utilising both polymer and small molecule synthesis techniques. The project expects to generate new copolymers and polymer networks that exploit molecular architecture to regulate the release profile of the active agents incorporated. The expected outcome is the establishment of design crit ....Next Generation Polymeric Scaffolds For Dual Agent Delivery. This project aims to provide a novel suite of degradable polymeric scaffolds for releasing multiple active agents with tailored release profiles by utilising both polymer and small molecule synthesis techniques. The project expects to generate new copolymers and polymer networks that exploit molecular architecture to regulate the release profile of the active agents incorporated. The expected outcome is the establishment of design criteria for tailoring the release of active agent from the polymer scaffold. This should provide significant benefits by developing a new technology platform that could be readily adapted to applications in agriculture, pharmaceutical science and veterinary medicine where controlled release is required.
Read moreRead less
Controlling the spatial distribution of targeting ligands on dendrimer surfaces as a means of dictating cellular recognition and fate. This project seeks to develop next generation targeted drug delivery systems that 'home' to specific target cells, including cancers. Targeted delivery systems have the potential to revolutionise therapy by providing bespoke drug distribution patterns that are tailored to specific diseases and result in enhanced activity and reduced toxicity.
Antibacterial Material Design via Mechanism-Based Mathematical Modelling. This Project aims to provide new rules for the design of novel polymer materials with antibacterial properties by employing mechanism-based mathematical modelling.
This Project expects to generate new understanding of those mechanisms which underpin the antibacterial activity of these materials, how bacteria respond to these through metabolic changes and emergence of resistance.These rules will govern material design to yi ....Antibacterial Material Design via Mechanism-Based Mathematical Modelling. This Project aims to provide new rules for the design of novel polymer materials with antibacterial properties by employing mechanism-based mathematical modelling.
This Project expects to generate new understanding of those mechanisms which underpin the antibacterial activity of these materials, how bacteria respond to these through metabolic changes and emergence of resistance.These rules will govern material design to yield new antibacterial materials with improved properties.
Expected outcomes of this project may be a novel mechanism-based mathematical model that will enable the next-generation of antibacterial materials.
This outcome will help address the increasing economic and social burden of antibiotic drug resistance in Australia.
Read moreRead less
Environmentally Sustainable Solvents for Natural Pharmaceutical Extraction Processes. Australia supplies 25 per cent of the world's pain relieving medicinal opiates which contributes to a $200 million export industry for Australia. The active pharmaceutical ingredients are extracted and purified at GlaxoSmithKline’s (GSK) Port Fairy processing plant using a solvent extraction based process. Together with GSK the project team aim to examine the use of environmentally sustainable bio-derived natur ....Environmentally Sustainable Solvents for Natural Pharmaceutical Extraction Processes. Australia supplies 25 per cent of the world's pain relieving medicinal opiates which contributes to a $200 million export industry for Australia. The active pharmaceutical ingredients are extracted and purified at GlaxoSmithKline’s (GSK) Port Fairy processing plant using a solvent extraction based process. Together with GSK the project team aim to examine the use of environmentally sustainable bio-derived natural solvents to replace the volatile organic compound (VOC) fossil fuels based solvents used in the current process. Due to environmental and health concerns associated with VOCs the development of alternative solvents will be of great benefit to not only GSK but a range of other processing industries that also use VOC based solvent extraction processes.Read moreRead less
Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.